The startup has developed a medical device that re-vascularizes the brain during the acute phase of ischemic stroke, enhancing cerebral perfusion and reducing associated disabilities. This technology enables clinicians to provide rapid diagnosis and immediate treatment, ultimately lowering in-patient costs.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current revascularization treatments for ischemic stroke, such as chemical or mechanical interventions, are not an option for all patients. Many patients are ineligible, leaving them without effective treatment options to restore cerebral perfusion. This results in acquired handicaps and significant healthcare costs.
Solution
Neuraltide offers the Swell-Suit, a non-invasive, lower-body positive-pressure device designed to enhance cerebral perfusion in ischemic stroke patients. The Swell-Suit redistributes blood from the lower body towards the heart and brain by increasing peripheral resistance. This action reduces the area of the brain at risk of irreversible ischemia, potentially reducing stroke-related disabilities. The device is designed to be easy to use and can be implemented in various healthcare settings without requiring specialized skills from paramedical staff, under medical prescription. The Swell-Suit aims to extend the therapeutic window for stroke patients, offering a treatment option even when other revascularization methods are not feasible.
Target Audience
The primary target audience includes hospitals, clinics, and treatment centers that treat ischemic stroke patients, as well as the paramedical staff involved in stroke management.
Features
- Non-invasive medical device based on lower-body positive-pressure principle
- Improves cerebral perfusion by redistributing blood flow
- Easy to use, requiring no additional skills for paramedical staff (under medical prescription)
- Designed for use in hospitals, clinics, and treatment centers
- Aims to extend the therapeutic window for ischemic stroke patients up to 24 hours
- Patented technology (patent pending)